Blood test vs tumor result for predicting liver cancer return
Part of Cancer, Digestive system clinical trials.
This study checks whether a simple blood test (called ctDNA) can predict if liver cancer will come back after surgery. It compares the blood test to a standard lab result from the removed tumor, which may help doctors plan better follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with liver cancer (hepatocellular carcinoma) at an early or intermediate stage that can be removed with surgery.
- You are in good general health (able to carry out daily activities) and your liver function is well enough (Child-Pugh score A).
- You have not had any previous cancer treatment for this liver cancer.
- You are able to provide blood samples and your routine lab tests are within normal ranges.
- You do not have another active cancer (except for cured basal cell skin cancer, early cervical cancer, or early thyroid cancer) and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with early-stage liver cancer who are scheduled for surgery. It uses a simple blood test to look for tiny bits of tumor DNA after treatment, which may help predict if the cancer will come back.
This trial uses a simple blood test to check for signs of liver cancer coming back after surgery. It may help doctors catch a return earlier and guide further treatment.
This trial studies whether a blood test can predict if liver cancer comes back after surgery or ablation, and whether an immunotherapy drug (PD-1 inhibitor) can help prevent recurrence. It may help guide treatment to keep the cancer from returning.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
This study uses a simple blood test to monitor tiny pieces of tumor DNA (ctDNA) in people with colorectal cancer that spread to the liver or with liver cancer (HCC), before and after liver surgery or transplant. It aims to help doctors detect cancer return earlier and guide treatment.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
Hear when a new Hepatocellular Carcinoma Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.